Multi-parametric magnetic resonance diagnosis and staging of liver disease
Described herein are systems and methods for performing multi-parametric diagnosis for liver disease. Systems and methods as described herein can include positioning a subject-in association with a medical imaging device and using the medical imaging device to measure the subject's liver for extracellular fluid and iron content. Systems and methods as described herein can further include determining whether iron overload may be indicated or present from the measurement for iron content, and if indicated, correcting the measurement for extra cellular fluid. Systems and methods as described herein can further include measuring the liver for hepatic lipid content (HLC). Systems and methods as described herein can determine the presence or absence of liver disease from measurements obtained from a subject. In certain embodiments, the medical imaging device is a magnetic resonance (MR) scanner. In certain embodiments, the liver is measured for iron overload.
1. A computer-implemented method for determining the presence or absence of liver disease in a subject, the method comprising the steps:
a) positioning a subject in association with a magnetic resonance (MR) scanner;
b) obtaining a measured value of the subject's liver for extracellular fluid using the magnetic resonance (MR) scanner, wherein the measured value of the subject's liver for extracellular fluid is obtained by using T1 mapping;
c) from a measurement for the iron content of the subject's liver which has been obtained from the subject's liver determining whether iron overload is indicated;
(d) if iron overload is indicated, correcting the measured value for extracellular fluid in the subject's liver; and
(e) determining from:
(i) the measurement for the iron content of the subject's liver,
(ii) the corrected measurement for the extracellular fluid in the subject's liver, and
(iii) a measurement for the hepatic lipid content (HLC) of the subject's liver which has been obtained from the subject's liver, wherein the measurement of the subject's liver for hepatic lipid content (HLC) is obtained by using one or more of MR spectroscopy, Dixon in and out of phase imaging, or dual-echo techniques,
a presence or absence of liver disease in the subject.
2. The method of claim 1 , wherein the measured value of the subject's liver for extracellular fluid is obtained by using T1 mapping, the measurement of the subject's liver for iron content is obtained by using T2* imaging and the measurement of the subject's liver for hepatic lipid content is obtained by using MR spectroscopy.
3. The method of claim 2 , wherein the measurement of the subject's liver for hepatic lipid content is obtained by using 1 H MR spectroscopy.
4. The method of claim 2 , wherein the T1 mapping is performed using a modified Look Locker inversion (MOLLI) recovery pulse sequence or a shortened modified Look Locker inversion recovery (Sh-MOLLI) sequence.
5. The method of claim 1 , wherein the measurement of the subject's liver for iron content is obtained by using one or more of T2 mapping, T2* mapping, measuring one or more blood biomarkers, or MR spectroscopy.
6. The method of claim 1 , wherein the liver disease consists of one or more of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), high hepatic lipid content, hepatic fibrosis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, viral hepatitis, chronic hepatitis, drug-induced hepatitis, haemochromatosis, thalassaemia, alcoholic hepatitis, alcoholic liver cirrhosis, portal hypertension, vascular liver disease, idiopathic hepatic fibrosis, sarcoidosis, hepatic cysts, or hemangiomas.
7. A system, comprising:
a magnetic resonance (MR) scanner;
at least one computing device;
at least one application executable in the at least one computing device, the at least one application comprising logic that:
a) obtains a measured value of a subject's liver for extracellular fluid using the magnetic resonance (MR) scanner, wherein the measured value of the subject's liver for extracellular fluid is obtained by using T1 mapping;
b) from a measurement for the iron content of the subject's liver which has been obtained from the subject's liver, determines whether iron overload is indicated;
c) if iron overload is indicated, corrects the measured value for extracellular fluid in the subject's liver; and
d) determines from:
(i) the measurement for the iron content of the subject's liver,
(ii) the corrected measurement for the extracellular fluid in the subject's liver, and
(iii) a measurement for the hepatic lipid content (HLC) of the subject's liver which has been obtained from the subject's liver, wherein the measurement of the subject's liver for hepatic lipid content (HLC) is obtained by using one or more of MR spectroscopy, Dixon in and out of phase imaging, or dual-echo techniques,
a presence or absence of liver disease in the subject.
8. The system of claim 7 , wherein the measured value of the subject's liver for extracellular fluid is obtained by using T1 mapping, the measurement of the subject's liver for iron content is obtained by using T2* imaging and the measurement of the subject's liver for hepatic lipid content is obtained by using MR spectroscopy.
9. The system of claim 8 , wherein the measurement of the subject's liver for hepatic lipid content is obtained by using 1 H MR spectroscopy.
10. The system of claim 8 , wherein the T1 mapping is performed using a modified Look Locker inversion (MOLLI) recovery pulse sequence or a shortened modified Look Locker inversion recovery (Sh-MOLLI) sequence.
11. The system of claim 7 , wherein the measurement of the subject's liver for iron content is obtained by using one or more of one or more of T2 mapping, T2* mapping, measuring one or more blood biomarkers, or MR spectroscopy.
12. The system of claim 7 , wherein the liver disease consists of one or more of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), high hepatic lipid content, hepatic fibrosis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, viral hepatitis, chronic hepatitis, drug-induced hepatitis, haemochromatosis, thalassaemia, alcoholic hepatitis, alcoholic liver cirrhosis, portal hypertension, vascular liver disease, idiopathic hepatic fibrosis, sarcoidosis, hepatic cysts, or hemangiomas.